LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 838

Search options

  1. Article ; Online: Adjuvant Chemotherapy in Older Women With Early Breast Cancer.

    Trapani, Dario

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2023  Volume 41, Issue 9, Page(s) 1652–1658

    Abstract: The Oncology Grand Rounds series is designed to place original reports published in ... ...

    Abstract The Oncology Grand Rounds series is designed to place original reports published in the
    MeSH term(s) Humans ; Female ; Aged ; Breast Neoplasms/drug therapy ; Docetaxel/therapeutic use ; Neoplasm Recurrence, Local/drug therapy ; Capecitabine/therapeutic use ; Chemotherapy, Adjuvant
    Chemical Substances Docetaxel (15H5577CQD) ; Capecitabine (6804DJ8Z9U)
    Language English
    Publishing date 2023-01-30
    Publishing country United States
    Document type Review ; Journal Article
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.22.02477
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1847: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 650: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Unveiling the Untapped Potential of Antibody Drug Conjugates in Precision Oncology.

    Trapani, Dario / Katrini, Jalissa / Curigliano, Giuseppe

    JAMA oncology

    2024  

    Language English
    Publishing date 2024-03-14
    Publishing country United States
    Document type Journal Article
    ISSN 2374-2445
    ISSN (online) 2374-2445
    DOI 10.1001/jamaoncol.2024.0008
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: What's the reality for CDK4/6 inhibitors: Clinical trials or real-world evidence?

    Trapani, Dario / Mayer, Erica L

    Cancer

    2023  Volume 129, Issue 7, Page(s) 986–988

    MeSH term(s) Humans ; Female ; Cyclin-Dependent Kinase 4 ; Cyclin-Dependent Kinase 6 ; Breast Neoplasms/drug therapy ; Protein Kinase Inhibitors/therapeutic use
    Chemical Substances Cyclin-Dependent Kinase 4 (EC 2.7.11.22) ; Cyclin-Dependent Kinase 6 (EC 2.7.11.22) ; Protein Kinase Inhibitors ; CDK4 protein, human (EC 2.7.11.22)
    Language English
    Publishing date 2023-02-09
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 1429-1
    ISSN 1097-0142 ; 0008-543X ; 1934-662X
    ISSN (online) 1097-0142
    ISSN 0008-543X ; 1934-662X
    DOI 10.1002/cncr.34672
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.146: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Mechanisms of Endocrine Resistance in Hormone Receptor-Positive Breast Cancer.

    Marra, Antonio / Trapani, Dario / Ferraro, Emanuela / Curigliano, Giuseppe

    Cancer treatment and research

    2024  Volume 188, Page(s) 219–235

    Abstract: Hormone receptor-positive (HR+) breast cancer (BC) accounts for approximately 70% of all breast invasive tumors. Endocrine therapy (ET) represents the standard treatment for HR + BC. Most patients, however, eventually develop resistance to ET, which ... ...

    Abstract Hormone receptor-positive (HR+) breast cancer (BC) accounts for approximately 70% of all breast invasive tumors. Endocrine therapy (ET) represents the standard treatment for HR + BC. Most patients, however, eventually develop resistance to ET, which limits their effectiveness and poses a major challenge for the management of HR + BC. Several mechanisms that contribute to ET resistance have been described. One of the most common mechanisms is the upregulation of alternative signaling pathways that can bypass estrogen dependency, such as activation of the PI3K/Akt/mTOR as well as mitogen-activated protein kinase (MAPK) and the insulin-like growth factor 1 receptor (IGF-1R) pathways. Another common mechanism of endocrine resistance is the acquisition of activating mutations of ESR1, which encodes for the estrogen receptor, that lead to structural changes of the receptor, prevent the binding to anti-estrogen drugs and result in constitutive activation of the receptor, even in the absence of estrogens. Epigenetic changes, such as DNA methylation and histone modifications, can also contribute to ET resistance by altering the expression of genes that are involved in estrogen signaling. Understanding the mechanisms of resistance to ET is crucial for the development of new therapies that can overcome resistance and improve outcomes for patients with HR + BC.
    MeSH term(s) Humans ; Female ; Breast Neoplasms/drug therapy ; Breast Neoplasms/genetics ; Phosphatidylinositol 3-Kinases ; Estrogens ; Receptors, Estrogen ; Signal Transduction
    Chemical Substances Phosphatidylinositol 3-Kinases (EC 2.7.1.-) ; Estrogens ; Receptors, Estrogen
    Language English
    Publishing date 2024-01-04
    Publishing country United States
    Document type Journal Article
    ISSN 0927-3042
    ISSN 0927-3042
    DOI 10.1007/978-3-031-33602-7_9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Next-Generation Sequencing for Advanced Breast Cancer: What the Way to Go?

    Trapani, Dario / Crimini, Edoardo / Sandoval, José / Curigliano, Giuseppe

    Cancer treatment and research

    2024  Volume 188, Page(s) 343–351

    Abstract: The rapid implementation of precision medicine tools in diagnosing and treating breast cancer (BC) has widened the potential therapeutic options for patients. The applications of gene sequencing, including next-generation gene sequencing (NGS), have led ... ...

    Abstract The rapid implementation of precision medicine tools in diagnosing and treating breast cancer (BC) has widened the potential therapeutic options for patients. The applications of gene sequencing, including next-generation gene sequencing (NGS), have led to numerous questions on how to validate, implement, interpret, prioritize and operationalize precision medicine tools to deliver meaningful and impactful interventions. Limited benefit has been portended with earlier experiences of NGS-driven treatment, in BC. However, the development and use of frameworks of clinical actionability of genomic alterations, for example, detected with NGS, has resulted in better patient selection, and potentially higher therapeutic value. The European Society for Medical Oncology Scale for Clinical Actionability of molecular Targets (ESCAT) is a framework that includes five tiers of clinical actionability, with tier 1 reserved for approved drugs with demonstrated benefits for targetable genomic alterations. The re-analysis of clinical studies by grouping the genomic alterations and matched drugs with ESCAT, in high vs lower tiers has demonstrated a significant benefit portended by high tiers alterations, with the availability of efficacious treatments. As a result, frameworks for actionability, like ESCAT, should be fundamental in developing and implementing NGS-driven, and broadly, precision medicine research and treatments.
    MeSH term(s) Humans ; Female ; Breast Neoplasms/diagnosis ; Breast Neoplasms/genetics ; Breast Neoplasms/therapy ; High-Throughput Nucleotide Sequencing ; Precision Medicine ; Genomics ; Medical Oncology
    Language English
    Publishing date 2024-01-04
    Publishing country United States
    Document type Journal Article
    ISSN 0927-3042
    ISSN 0927-3042
    DOI 10.1007/978-3-031-33602-7_13
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Antibody-drug conjugates targeting HER2-mutant or HER2-(non) amplified solid tumors: is HER2 an agnostic target?

    Guidi, Lorenzo / Valenza, Carmine / Trapani, Dario / Curigliano, Giuseppe

    Expert opinion on biological therapy

    2023  Volume 23, Issue 11, Page(s) 1039–1042

    MeSH term(s) Humans ; Immunoconjugates/pharmacology ; Immunoconjugates/therapeutic use ; Neoplasms/drug therapy ; Neoplasms/genetics ; Receptor, ErbB-2/genetics
    Chemical Substances Immunoconjugates ; Receptor, ErbB-2 (EC 2.7.10.1)
    Language English
    Publishing date 2023-12-15
    Publishing country England
    Document type Editorial
    ZDB-ID 2052501-1
    ISSN 1744-7682 ; 1471-2598
    ISSN (online) 1744-7682
    ISSN 1471-2598
    DOI 10.1080/14712598.2023.2277915
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6094: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Accesso alle cure oncologiche: difficoltà finanziarie, sostenibilità del sistema, rigore metodologico.

    Giusti, Raffaele / Trapani, Dario

    Recenti progressi in medicina

    2022  Volume 113, Issue 12, Page(s) 701–704

    Abstract: The growing national economic burden linked to cancer spending is certainly impacted by an aging population, yet it finds its greatest obstacle in the ever-increasing costs for diagnostics, therapies, and hospital care, putting a strain on patients' ... ...

    Title translation Access to cancer treatment: financial difficulties, system sustainability, methodological rigor. The role of scientific journals.
    Abstract The growing national economic burden linked to cancer spending is certainly impacted by an aging population, yet it finds its greatest obstacle in the ever-increasing costs for diagnostics, therapies, and hospital care, putting a strain on patients' finances of the family and the health system. Even in a universal healthcare system like the Italian one, where much of the difficult decisions on healthcare spending are in the hands of government technicians, and shaped by political will, patients contribute to cancer costs out of their own pockets to a much greater extent than is perceived from common sense. The sustainability of the cancer care system cannot ignore the meticulous control of public spending, which is fundamental and essential for societies that aim to keep the standards of care extremely high and continuously improve access and reduce inequalities in cancer care. Clinical trials, healthcare professionals and patients are best placed to evaluate the costs and benefits of treatment choices and are among the most financially affected by such decisions. Can scientific journals in the sector have their contribution for improvement? How can journals potentially close this gap and inform doctors, taxpayers, and the general population? To address this problem effectively, attention needs to be paid to two fundamental issues: one is high-quality science, and another is the ability to inform decision-making.
    MeSH term(s) Humans ; Aged ; Periodicals as Topic ; Neoplasms/therapy ; Health Personnel ; Physicians ; Aging
    Language Italian
    Publishing date 2022-11-25
    Publishing country Italy
    Document type English Abstract ; Journal Article
    ZDB-ID 138266-4
    ISSN 2038-1840 ; 0034-1193
    ISSN (online) 2038-1840
    ISSN 0034-1193
    DOI 10.1701/3914.38971
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 193: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Immunotherapy for inflammatory breast cancer: current evidences and future perspectives.

    Valenza, Carmine / Trapani, Dario / Curigliano, Giuseppe

    Current opinion in oncology

    2023  Volume 35, Issue 6, Page(s) 507–512

    Abstract: Purpose of review: Inflammatory breast cancer (IBC) is the most fatal type presentation of clinical breast cancer. The immune tumor microenvironment (TME) of IBC is characterized by signals of immune evasion but suggests actionable vulnerability to ... ...

    Abstract Purpose of review: Inflammatory breast cancer (IBC) is the most fatal type presentation of clinical breast cancer. The immune tumor microenvironment (TME) of IBC is characterized by signals of immune evasion but suggests actionable vulnerability to immune-checkpoint inhibitors (ICIs). In this review, we aimed to summarize the most important preclinical evidences of IBC immune-vulnerability and the first data from clinical trials evaluating ICIs in IBC.
    Recent findings: IBC is characterized by a preexisting active immune TME suppressed by mechanisms of immune-escape, including inhibitory immune-checkpoints, whose expression is higher than in non-IBC. Clinical trials evaluating ICIs in patients with IBC are burdened by slow accrual and low enrollment.
    Summary: Because of the limited data from clinical trials, no conclusions about the activity of ICIs in IBC can be drawn. Ongoing clinical trials are assessing many promising ICI-based combination approaches. An enhanced multicenter collaboration to evaluate ICIs in patients with this aggressive form of disease and to improve clinical outcomes is required.
    Language English
    Publishing date 2023-06-26
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1049384-0
    ISSN 1531-703X ; 1040-8746
    ISSN (online) 1531-703X
    ISSN 1040-8746
    DOI 10.1097/CCO.0000000000000967
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3046: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Optimizing Postneoadjuvant Treatment in Patients With Early Breast Cancer Achieving Pathologic Complete Response.

    Valenza, Carmine / Trapani, Dario / Loibl, Sibylle / Chia, Stephen K L / Burstein, Harold J / Curigliano, Giuseppe

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2024  , Page(s) JCO2301935

    Abstract: pCR should be integrated with other prognostic factors to optimize postneoadjuvant treatments in BC. ...

    Abstract pCR should be integrated with other prognostic factors to optimize postneoadjuvant treatments in BC.
    Language English
    Publishing date 2024-04-03
    Publishing country United States
    Document type Journal Article
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.23.01935
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1847: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 650: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: COVID-19 vaccines in patients with cancer.

    Trapani, Dario / Curigliano, Giuseppe

    The Lancet. Oncology

    2021  Volume 22, Issue 6, Page(s) 738–739

    MeSH term(s) COVID-19 ; COVID-19 Vaccines ; Humans ; Neoplasms/therapy ; Prospective Studies ; SARS-CoV-2
    Chemical Substances COVID-19 Vaccines ; BNT162 vaccine (N38TVC63NU)
    Language English
    Publishing date 2021-06-04
    Publishing country England
    Document type Journal Article ; Comment
    ZDB-ID 2049730-1
    ISSN 1474-5488 ; 1470-2045
    ISSN (online) 1474-5488
    ISSN 1470-2045
    DOI 10.1016/S1470-2045(21)00250-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5696: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 460: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top